Business
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Leen Kawas, president and CEO of Athira Pharma, comes from a long line of successful, trailblazing women who place an emphasis on inspiring the next generation, and she is driven to defeat neurodegenerative disease, which has stolen two of those women from her.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
BioSpace recently spoke with Jonathan Rigby, Group CEO of Revolo Biotherapeutics, a biotherapeutic company working to revolutionize the treatment of autoimmune and allergic disease by achieving superior long-term disease remission through resetting the immune system.
Theranos founder Elizabeth Holmes is back in the courtroom for the first time in 15 months for a three-day hearing ahead of her criminal fraud trial.
Here’s a look at Pfizer-BioNTech, Novavax and the COVID-19 vaccine’s sales, approval in children, additional trials, potential of booster shots, and more.
Roger Perlmutter, the former president of Merck Research Laboratories, will helm drug discovery startup Eikon Therapeutics, Inc.
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
April showers bring May dollars. Here’s whose cash gardens are really blooming this week in the life sciences world.
Companies across the biotech and biopharma industries recently reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine.